[
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975666",
    "id": "02975666",
    "pages": 2,
    "price_sensitive": false,
    "date": "20250801",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwwc2rtwrgv.pdf",
    "summary": "<ul>\n<li><strong>FY26 operating profit guidance</strong>: $20.0 to $24.0 million.  </li>\n<li><strong>Revenue target for FY27</strong>: $300 million.  </li>\n<li><strong>R&amp;D pipeline</strong>: Targets addressable markets worth over <strong>US$8 billion</strong>, with 8 patented products and 24 off-patent injectables in development.  </li>\n<li><strong>Key commercialisation programs</strong>: Maxigesic\u00ae, Crystaderm\u00ae, Micolette\u00ae, Kiwisoothe\u00ae, and capsaicin cream.  </li>\n</ul>\n<p><em>No material capital markets or trading-specific actions identified (e.g., capital raising, trading halt).</em></p>",
    "usage": {
      "prompt_tokens": 1072,
      "completion_tokens": 122,
      "total_tokens": 1194,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-31T21:46:03.455663"
  },
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975667",
    "id": "02975667",
    "pages": 4,
    "price_sensitive": false,
    "date": "20250801",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwygggfj5k9.pdf",
    "summary": "<ul>\n<li><strong>Revenue milestone</strong>: Achieved record sales of $208 million (first time exceeding $200 million).  </li>\n<li><strong>Geographic expansion</strong>: Launched Maxigesic IV and Combogesic Rapid in the US; began sales of Maxigesic IV in Canada (addressable market &gt;US$8 billion).  </li>\n<li><strong>Financials</strong>: Net debt reduced to $14.5 million (from $16.2 million); dividend increased to 1.8 cents/share (from 1.6 cents).  </li>\n<li><strong>R&amp;D pipeline</strong>: 8 patented products in development, 24 off-patent injectables, and 5 programs nearing commercialization (e.g., Maxigesic variants, Crystaderm).  </li>\n<li><strong>FY27 target</strong>: Ambitious $300 million revenue goal.  </li>\n</ul>\n<p><em>Note: No capital markets actions (e.g., raising, halt) or urgent trading signals identified.</em></p>",
    "usage": {
      "prompt_tokens": 1984,
      "completion_tokens": 184,
      "total_tokens": 2168,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-31T21:46:58.501346"
  },
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975668",
    "id": "02975668",
    "pages": 30,
    "price_sensitive": false,
    "date": "20250801",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdx0kbh3x5mq.pdf",
    "summary": "<p><strong>Summary of AFT Pharmaceuticals 2025 Annual Shareholders' Meeting Announcement</strong>  </p>\n<h3><strong>Financial &amp; Operational Highlights</strong></h3>\n<ul>\n<li><strong>FY25 Revenue</strong>: NZ$208.0M (6% YoY growth), with ANZ sales at NZ$180.9M.  </li>\n<li><strong>FY27 Target</strong>: Revenue of NZ$300M.  </li>\n<li><strong>Operating Profit</strong>: NZ$17.6M (down from NZ$24.2M in FY24 due to lower licensing income and strategic investments).  </li>\n<li><strong>Dividend</strong>: Increased to 1.8 cents per share (from 1.6 cps in FY24).  </li>\n<li><strong>Net Debt</strong>: NZ$14.5M (down from NZ$16.2M in FY24).  </li>\n<li><strong>R&amp;D Spend</strong>: NZ$15.0M (FY25), focused on 8 patented products and 24+ injectables.  </li>\n</ul>\n<h3><strong>Market Expansion &amp; Strategy</strong></h3>\n<ul>\n<li><strong>Global Reach</strong>: Products sold in ~80 countries; distribution agreements in 100+ countries.  </li>\n<li><strong>Key Markets</strong>: Growth in Australasia (NZ: NZ$53.8M; Australia: NZ$127.1M), hampered by disruptions in Asia (NZ$15.4M, down from NZ$19.3M).  </li>\n<li><strong>New Hubs</strong>: Launches in EU, UK, USA, Canada, South Africa, Hong Kong, and Singapore, with pipelines of 17\u201340 products per region.  </li>\n</ul>\n<h3><strong>R&amp;D Pipeline Highlights</strong></h3>\n<ul>\n<li><strong>Near-Term</strong>: 24 hospital injectables (filing 2025\u20132027), Migraine project (filing 1Q27), Pascomer (PWS treatment, filing 2027).  </li>\n<li><strong>Long-Term</strong>: Antibiotic eye drop (2028), Keloid scar topical (2029), Burning Mouth Syndrome (2030).  </li>\n</ul>\n<h3><strong>Governance Resolutions</strong></h3>\n<ol>\n<li>Auditor remuneration approval (Deloitte).  </li>\n<li>Re-election of Dr. Hartley Atkinson as Director.  </li>\n<li>Election of Allison Yorston as Director.  </li>\n</ol>\n<h3><strong>Outlook</strong></h3>\n<ul>\n<li><strong>FY26 Operating Profit Guidance</strong>: NZ$20M\u2013NZ$24M.  </li>\n<li>Focus on product launches, international growth, and R&amp;D commercialization.  </li>\n</ul>\n<p><strong>Omitted</strong>: Director names, boilerplate, historical background, and non-material operational details.</p>",
    "usage": {
      "prompt_tokens": 5861,
      "completion_tokens": 491,
      "total_tokens": 6352,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-31T21:46:35.883463"
  }
]